H.C. Wainwright sees 'catalyst-rich' 2022 for Australia's Kazia Therapeutics

Kazia Therapeutics

07/12/2021 21:03

** H.C. Wainwright & Co believes that positive results from
ongoing clinical studies could become "major" catalysts for
Australia's Kazia Therapeutics next year  KZA.AX 
    ** The oncology-focused drug developer announced positive
final data from the Phase II clinical study of its paxalisib
drug for glioblastoma multiforme (GBM) last week  urn:newsml:reuters.com:*:nASX3j4PFm
    ** Brokerage considers the unmet need in the treatment of
GBM, an aggressive cancer on brain or spine, and believes that
paxalisib has the potential to become the new treatment of
choice for this condition
    ** Reiterates its "buy" rating and says it is also expecting
KZA to report interim results for various ongoing clinical
studies in 2022
    ** One analyst rates the stock "buy", median PT is A$2.40 -
Refinitiv data
    ** As of last close, KZA has gained 2.2% this year

 (Reporting by Himanshi Akhand in Bengaluru)
 ((Himanshi.Akhand@thomsonreuters.com;))